MiMedx Group Inc (MDXG) : Simplex Trading scooped up 5,353 additional shares in MiMedx Group Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Oct 7, 2016. The investment management firm now holds a total of 68,416 shares of MiMedx Group Inc which is valued at $604,113.MiMedx Group Inc makes up approximately 0.08% of Simplex Trading’s portfolio.
Other Hedge Funds, Including , Bnp Paribas Arbitrage Sa reduced its stake in MDXG by selling 17,071 shares or 54.66% in the most recent quarter. The Hedge Fund company now holds 14,162 shares of MDXG which is valued at $125,617. Eqis Capital Management sold out all of its stake in MDXG during the most recent quarter. The investment firm sold 36,039 shares of MDXG which is valued $319,666.
MiMedx Group Inc closed down -0.03 points or -0.34% at $8.83 with 4,47,268 shares getting traded on Friday. Post opening the session at $8.86, the shares hit an intraday low of $8.65 and an intraday high of $8.87 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.
On the company’s financial health, MiMedx Group Inc reported $0.05 EPS for the quarter, missing the analyst consensus estimate by $ -0.02 based on the information available during the earnings call on Jul 26, 2016. Analyst had a consensus of $0.07. The company had revenue of $57.34 million for the quarter, compared to analysts expectations of $56.20 million. The company’s revenue was up 25.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.05 EPS.
MiMedx Group Inc. (MiMedx) is an integrated developer manufacturer and marketer of regenerative biomaterial products and bioimplants processed from human amniotic membrane. The Company’s biomaterial platform technologies include AmnioFix and EpiFix its tissue technologies processed from human amniotic membrane that is derived from donated placentas. Through its donor program mothers delivering full-term Cesarean section births can elect in advance of delivery to donate the placenta in lieu of having it discarded as medical waste. MiMedx processes the human amniotic membrane utilizing its Purion Process to produce an implant which is referred as an allograft. MiMedx is the supplier of amniotic tissue having supplied over 350000 allografts for application in the Wound Care Surgical Sports Medicine Ophthalmic and Dental sectors of healthcare. Its CollaFix technology combines a means of creating fibers from soluble collagen and a cross-linking process.